טוען...
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis
BACKGROUND: Interferon (IFN) beta-1a is an approved treatment for relapsing remitting multiple sclerosis (RRMS) and has been examined for use in secondary progressive multiple sclerosis (SPMS). However, no information regarding blood transcriptional changes induced by IFN treatment in SPMS patients...
שמור ב:
| הוצא לאור ב: | BMC Neurol |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4654830/ https://ncbi.nlm.nih.gov/pubmed/26589141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-015-0495-x |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|